Anti-CXCL5 antibody [EPR4450(2)]
- 20ul selling size
- KO Validated
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(9 Publications)
Knockout Tested Rabbit Recombinant Monoclonal CXCL5 antibody. Suitable for IP, WB and reacts with Human samples. Cited in 9 publications.
View Alternative Names
ENA78, SCYB5, CXCL5, C-X-C motif chemokine 5, ENA-78(1-78), Epithelial-derived neutrophil-activating protein 78, Neutrophil-activating peptide ENA-78, Small-inducible cytokine B5
- IP
Lab
Immunoprecipitation - Anti-CXCL5 antibody [EPR4450(2)] (AB126763)
CXCL5 was immunoprecipitated from 0.35 mg A549 (Human lung carcinoma epithelial cell) whole cell lysate 10 μg with 126763 at 1/50 dilution (2μg). VeriBlot for IP Detection Reagent (HRP) (ab131366) was used at 1/5000 dilution.
Lane 1 : A549 (Human lung carcinoma epithelial cell) whole cell lysate 10 μg
Lane 2 : ab126763 IP in A549 whole cell lysate
Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab126763 in A549 whole cell lysate
Blocking and dilution buffer and concentration : 5% NFDM/TBST.
All lanes:
Immunoprecipitation - Anti-CXCL5 antibody [EPR4450(2)] (ab126763)
Predicted band size: 12 kDa
Observed band size: 12 kDa
false
- WB
Unknown
Western blot - Anti-CXCL5 antibody [EPR4450(2)] (AB126763)
All lanes:
Western blot - Anti-CXCL5 antibody [EPR4450(2)] (ab126763) at 1/1000 dilution
Lane 1:
A549 cell lysate, treated with TNF alpha and TPA at 10 µg
Lane 2:
A549 cell lysate, untreated at 10 µg
Lane 3:
Human CXCL5 recombinant protein at 0.001 µg
Secondary
All lanes:
Goat anti-Rabbit HRP at 1/2000 dilution
Predicted band size: 12 kDa
false
- WB
Supplier Data
Western blot - Anti-CXCL5 antibody [EPR4450(2)] (AB126763)
False colour image of Western blot : Anti-CXCL5 antibody [EPR4450(2)] staining at 1/1000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab126763 was shown to bind specifically to CXCL5. A band was observed at 7 kDa in treated wild-type A549 cell lysates with no signal observed at this size in CXCL5 knockout cell line ab275838 (knockout cell lysate ab275812). To generate this image, wild-type and CXCL5 knockout A549 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution.
All lanes:
Western blot - Anti-CXCL5 antibody [EPR4450(2)] (ab126763) at 1/1000 dilution
Lane 1:
Wild-type A549 Untreated Control cell lysate at 20 µg
Lane 2:
Wild-type A549 Treated TNFa (10 ng/mL, 24 h) + PMA (10 nM, 24 h) cell lysate at 20 µg
Lane 3:
CXCL5 knockout A549 Untreated Control cell lysate at 20 µg
Lane 4:
CXCL5 knockout A549 Treated TNFa (10 ng/mL, 24 h) + PMA (10 nM, 24 h) cell lysate at 20 µg
Secondary
All lanes:
Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution
Predicted band size: 12 kDa
Observed band size: 7 kDa
false
- OI-RD Scanning
Unknown
OI-RD Scanning - Anti-CXCL5 antibody [EPR4450(2)] (AB126763)
We have systematically measured KD (the equilibrium dissociation constant between the antibody and its antigen), of more than 840 recombinant antibodies to assess not only their individual KD values but also to see the average affinity of antibody. Based on the comparison with published literature values for mouse monoclonal antibodies, Recombinant antibodies appear to be on average 1-2 order of magnitude higher affinity.
Related conjugates and formulations (1)
-
Anti-CXCL5 antibody [EPR4450(2)] - BSA and Azide free
Reactivity data
Product details
Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please contact us for more information.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
CXCL5 affects inflammation and the immune response by modulating neutrophil recruitment to sites of infection or injury. It is a part of the larger network of chemokines that direct leukocyte movement throughout the body. While CXCL5 does not form a complex in a traditional sense it does interact dynamically with CXCR2 receptor to exert its effects. These interactions are pivotal to the protein’s role in orchestrating the immune system’s response to diverse stimuli.
Pathways
CXCL5 plays a part in the chemokine signaling pathway and the inflammatory response pathway. These pathways are important in mediating immune surveillance and inflammation. CXCL5 through these pathways has a strong connection to other CXC family proteins like CXCL1 and the receptor CXCR2 which allows for a coordinated response during immune challenges and recovery processes.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (9)
Recent publications for all applications. Explore the full list and refine your search
Frontiers in immunology 16:1548635 PubMed40313933
2025
Applications
Unspecified application
Species
Unspecified reactive species
Antioxidants (Basel, Switzerland) 13: PubMed39765818
2025
Applications
Unspecified application
Species
Unspecified reactive species
Cell discovery 10:109 PubMed39468013
2024
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 13:7796 PubMed36528626
2022
Applications
Unspecified application
Species
Unspecified reactive species
Analytical cellular pathology (Amsterdam) 2022:5418356 PubMed35936390
2022
Applications
Unspecified application
Species
Unspecified reactive species
Cell death discovery 8:243 PubMed35504887
2022
Applications
Unspecified application
Species
Unspecified reactive species
Human vaccines & immunotherapeutics 18:2065837 PubMed35486941
2022
Applications
Unspecified application
Species
Unspecified reactive species
Experimental and therapeutic medicine 21:301 PubMed33717244
2021
Applications
Unspecified application
Species
Unspecified reactive species
Microbiology and immunology 65:40-47 PubMed33026667
2021
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com